Serum lysyl oxidase like-2 levels and idiopathic pulmonary fibrosis disease progression.

Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T.
Journal   Eur Respir J.
Analytes Measured  
Matrix Tested   Serum
Year   2013
Page Numbers  
Application   Cytokines and Chemokines
We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathologic stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression (DP).Patients from ARTEMIS-IPF (n=69) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) study (n=104) were analysed. Baseline serum LOXL2 levels were compared to baseline clinical and physiologic surrogates of disease severity, and the association with IPF DP was assessed using a classification and regression tree (CART) method.sLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r range -0.24 to 0.05) in both cohorts. CART-determined thresholds were similar: ARTEMIS-IPF 800 pg·mL-1, GAP 700 pg·mL-1. In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL-1) was associated with increased risk for DP (hazard ratio [HR] 5.41, 95% confidence interval [CI] 1.65-17.73). Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL-1) were associated with more DP events (HR 1.78, 95% CI 1.01-3.11). Among all GAP subjects, higher sLOXL2 levels were associated with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).These results suggest that higher sLOXL2 levels are associated with increased risk for IPF DP. However, due to multiple limitations, these results require validation.

View Publications
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters